Feb 24, 2021 | Press Releases
The NantKwest Special Committee and the NantKwest Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 8, 2021 at 9:30 a.m. Pacific Time Stockholders are encouraged to vote, no matter how...Feb 24, 2021 | Press Releases
CULVER CITY, Calif., February 24, 2021 — ImmunityBio, Inc., a privately-held immunotherapy company, today announced the appointment of John Brennan, former Central Intelligence Agency Director, and Wesley Clark, retired U.S. Army General, to the company’s board of...Feb 16, 2021 | Press Releases
ImmunityBio Announces ASCO Genitourinary Cancer symposium presentation of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 71% Complete Response Rate QUILT 3.032 study completes planned enrollment of BCG unresponsive non-muscle...Feb 11, 2021 | Press Releases
FDA authorized the expansion of the active Phase 1 COVID-19 vaccine trial and a second trial to test a novel combination of T-cell-based hAd5 subcutaneous prime vaccine with a room-temperature oral or sublingual boost, to induce comprehensive immune protection through...Jan 28, 2021 | Press Releases
Clinical benefit observed in majority of NSCLC patients who progressed on checkpoint inhibitor AnktivaÔ (also called N-803) restored or enhanced activity of checkpoint therapy even in those who progressed on the same checkpoint Activity observed regardless of PD-L1...Jan 19, 2021 | Press Releases
Using Molecular Dynamic (MD) simulation, ImmunityBio scientists assessed the affinity of mutated spike receptor binding domain (RBD) of SARS-CoV-2 to its receptor on human cells, ACE2 The mutations studied occur in the new UK and South African strains that have spread...Jan 19, 2021 | Press Releases
Plans to study COVID-19 subcutaneous and oral, room-temperature capsule vaccineto protect against escape mutants ImmunityBio to conduct initial trial of its human adenovirus (hAd5) COVID-19 vaccine candidate in South Africa, where the 501Y.V2 strain has been recently...Jan 13, 2021 | Press Releases
Pivotal QUILT 88 trial based on combination immunotherapy of “Cancer Moonshot” strategy; early indications of increased survival rate for pancreatic cancer patients with no other approved treatment options In initial Cancer Moonshot QUILT trials of haNK and avelumab...Jan 6, 2021 | Press Releases
EL SEGUNDO, Calif., January 6, 2021 — NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Dr. Patrick Soon-Shiong M.D., Executive Chairman of the Board of Directors, will participate in the 39th Annual...Jan 4, 2021 | Press Releases
Detailed computer modeling, completed in partnership with Microsoft, explains virulence of COVID-19 and provides key information that may lead to a better understanding of the multiple mutations currently occurring to the “spike” protein as the virus evolves...